 ADENOCARCINOMA OF LUNG, SOMATIC
|
AORTIC ANEURYSM, FAMILIAL THORACIC 7
|
BREAST CANCER, SUSCEPTIBILITY TO
|
CARDIOFACIOCUTANEOUS SYNDROME 1
|
CARDIOFACIOCUTANEOUS SYNDROME 3
|
CARDIOFACIOCUTANEOUS SYNDROME 4
|
CATARACT 6, AGE-RELATED CORTICAL
|
CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH HIRSCHSPRUNG DISEASE
|
CHRONIC MYELOID LEUKEMIA, RESISTANT TO IMATINIB
|
COFFIN-LOWRY SYNDROME
|
COLON CANCER, SOMATIC
|
COLORECTAL CANCER, SOMATIC
|
COLORECTAL CANCER, SOMATIC, INCLUDED;;
|
COWDEN DISEASE 6
|
DIABETES MELLITUS, TYPE II
|
ENDOCRINE-CEREBROOSTEODYSPLASIA
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2 (EIEE2)
|
FG SYNDROME 4
|
GLYCOGEN STORAGE DISEASE 9C (GSD9C)
|
GLYCOGEN STORAGE DISEASE IXC
|
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1
|
IRAK4 DEFICIENCY
|
LEUKEMIA, PHILADELPHIA CHROMOSOME-POSITIVE, RESISTANT TO IMATINIB
|
LYMPHOMA, NON-HODGKIN, SOMATIC
|
LYMPHOPROLIFERATIVE SYNDROME 1
|
MALFORMATIONS
|
MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME
|
MELANOMA, MALIGNANT, SOMATIC
|
MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA
|
MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA (MICPCH)
|
MENTAL RETARDATION, X-LINKED 30
|
MENTAL RETARDATION, X-LINKED, WITH NYSTAGMUS
|
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA
|
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB
|
NEPHRONOPHTHISIS 9 (NPHP9)
|
NEUROPATHY, HEREDITARY SENSORY, TYPE II
|
NOONAN SYNDROME 7
|
OGUCHI DISEASE 2
|
PANCREATIC CANCER, SOMATIC
|
PEUTZ-JEGHERS SYNDROME
|
PHEOCHROMOCYTOMA, INCLUDED
|
PHEOCHROMOCYTOMA, SOMATIC, IN
|
RENAL AGENESIS
|
RETINITIS PIGMENTOSA 62
|
RETINITIS PIGMENTOSA 62 (RP62)
|
SHORT RIB-POLYDACTYLY SYNDROME 2A (SRPS2A)
|
SHORT RIB-POLYDACTYLY SYNDROME, TYPE IIA
|
SPERMATOGENIC FAILURE 5
|
T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AUTOIMMUNITY, AND CARDIAC
|
TESTICULAR TUMOR, SOMATIC
|
THYROID CARCINOMA, FAMILIAL MEDULLARY
|
THYROID CARCINOMA, FAMILIAL MEDULLARY, INCLUDED
|
THYROID CARCINOMA, FOLLICULAR, SOMATIC, INCLUDED
|
THYROID CARCINOMA, PAPILLARY, SOMATIC, INCLUDED;;|
|
THYROID CARCINOMA, SPORADIC MEDULLARY, INCLUDED;;
|
VARIANT OF UNKNOWN SIGNIFICANCE
|
Catalytic domain of the Protein Serine/Threonine Kinase, Thousand-and-one amino acids 3. Serine/threonine kinases (STKs), thousand-and-one amino acids 3 (TAO3) subfamily, catalytic (c) domain. STKs catalyze the transfer of the gamma-phosphoryl group from ATP to serine/threonine residues on protein substrates. The TAO subfamily is part of a larger superfamily that includes the catalytic domains of other protein STKs, protein tyrosine kinases, RIO kinases, aminoglycoside phosphotransferase, choline kinase, and phosphoinositide 3-kinase. TAO proteins possess mitogen-activated protein kinase (MAPK) kinase kinase (MAPKKK or MAP3K or MKKK) activity. MAPK signaling cascades are important in mediating cellular responses to extracellular signals. TAO3 is also known as JIK (JNK inhibitory kinase) or KFC (kinase from chicken). It specifically activates c-Jun N-terminal kinase (JNK), presumably by phosphorylating and activating MKK4/MKK7. In Saccharomyces cerevisiae, TAO3 is a component of the RAM (regulation of Ace2p activity and cellular morphogenesis) signaling pathway. TAO3 is upregulated in retinal ganglion cells after axotomy, and may play a role in apoptosis.
No pairwise interactions are available for this conserved domain.
